13.3 Pharmacovigilance, Recall & Medicine Disposal

Why Pharmacovigilance Exists

Pharmacovigilance (PV) is the science and activity of detecting, assessing, understanding and preventing adverse effects and other medicine-related problems after marketing authorisation. Pre-marketing clinical trials enrol limited, selected populations for limited durations, so they cannot detect rare reactions, long-latency harms, or effects in groups excluded from trials — pregnant women, the very old, patients with multiple comorbidities. Post-marketing surveillance by the whole health system is therefore the only realistic way to catch these signals, which is why regulators can restrict, re-label or withdraw products years after launch. The UAE participates in the international reporting network coordinated through the World Health Organization's programme, and operates a national system under the federal medicines regulator — the Emirates Drug Establishment (EDE) — with Dubai Health (DHA) providing reporting channels for facilities and professionals in Dubai.

Who reports, and what

Any healthcare professional — explicitly including pharmacists — should report, and patients may report too. The duty attaches to suspicion: you do not need to prove causality before reporting. Report:

• Serious suspected adverse drug reactions (ADRs) — fatal, life-threatening, causing hospitalisation, disability or congenital harm.
• Unexpected reactions — not consistent with the approved product information, even if mild.
• Reactions to new medicines under enhanced surveillance (the black-triangle concept used internationally: an inverted triangle on product information flags a new drug for intensive reporting of all suspected reactions).
• Medication errors that caused or could have caused harm, and lack of efficacy where it matters clinically (for example, contraceptive or anti-infective failure).
• Product quality defects — contamination, mislabelling, crumbling tablets, particulate matter in injections.

Minimum reportable information

A report is considered valid when it contains four elements — an easy exam mnemonic:

1. An identifiable patient (initials, age, sex suffice — not necessarily a name).
2. An identifiable reporter (so the authority can follow up).
3. A suspect drug (brand or generic name, strength, batch where known).
4. A suspected reaction (description, onset, outcome).

Reports are assessed for causality — the likelihood the drug caused the event, from certain through probable and possible to unlikely — using timing, dechallenge, rechallenge and alternative explanations. Pharmacists should know the concept and the factors, not a scoring formula.

Medicine Recalls

A recall is the removal or correction of a marketed product that violates standards or presents a risk. Recalls are graded by severity — the international convention used in regional guidance:

Pharmacy obligations on recall notification: identify and quarantine affected stock (physically segregate and label it so it cannot be dispensed), reconcile against the batch numbers in the notice, identify and contact patients who received the affected batch where the notice directs patient-level recall, document every step — quantities found, patients contacted, stock returned — and return or destroy the stock only through the authorised route specified by the authority or the marketing-authorisation holder. A defective product identified locally (before any recall) should likewise be quarantined, reported as a quality defect, and never dispensed or silently returned to the shelf.

Safe Disposal of Expired and Unused Medicines

Expired, damaged or unwanted medicines are pharmaceutical waste, not ordinary refuse. Core rules:

• Never dispose of medicines in household waste, and never flush them into sinks or toilets — sewage systems are not designed to remove pharmaceuticals, and landfill leaching contaminates the environment.
• Pharmacies accept or arrange the return of unwanted medicines from patients and channel expired stock to an authorised pharmaceutical-waste handler for high-temperature incineration or an equivalent approved method, with documented transfer.
• Controlled drugs require the stricter route already covered in Section 13.1: prior authorisation and witnessed, documented destruction, with the register annotated.
• Cytotoxic and hazardous medicines (chemotherapy agents, certain antivirals and hormones) are segregated into designated hazardous-waste containers and handled with protective precautions by trained handlers — they are never mixed with general pharmaceutical waste.
• Sharps — needles, lancets, broken ampoules — go immediately into a puncture-resistant sharps container, which is sealed and replaced before overfilling and disposed of through the clinical-waste stream. Never recap needles by hand, never place sharps in general waste bags, and never overfill past the fill line.

Selling expired stock, repackaging near-expiry products, or discarding medicines in ordinary rubbish are all exam-level examples of professional misconduct with regulatory and environmental consequences.